At OncoSil Medical we have one mission – to transform the prognosis for people with cancer.
Our first priority is pancreatic cancer. For 40 years the prognosis for this condition has remained almost unchanged. Less than 8% of patients with pancreatic cancer survive five years.† The statistics have left patients and doctors little room for hope. Until now.
OncoSil Medical is an innovative Australian biotechnology company focused on interventional oncology. We’re passionate about improving outcomes for people with pancreatic cancer. We believe it’s time to change the conversation around cancers with poor prognoses and transform the approach to their treatment. Our current focus is on unresectable locally advanced pancreatic cancer (LAPC).
OncoSil™ is our breakthrough‡ brachytherapy device.2,3 Unlike conventional external beam radiation therapy, OncoSil™ uses a targeted approach to deliver a calculated dose of radiation directly into the tumour. It enables doctors to target a greater radiation dose directly to the tumour, while sparing surrounding critical organs.4 The OncoSil™ device is intended for the treatment of unresectable locally advanced pancreatic cancer and is used in conjunction with chemotherapy.
Defying expectations takes courage from everyone involved, the confidence to think differently about treatment techniques, and an honest appreciation of the challenges we face.
Pancreatic cancer and specifically LAPC present great challenges but at OncoSil Medical we are driven by a desire to do better for people with cancer and our determination remains to transform the prognosis for people with pancreatic cancer.
†Age-standardised 5-year net survival of 7.3% (95% CI 6.9–7.7%; adults aged 15–99, England, 2013-2017).1 ‡OncoSil™ has received breakthrough device designation in the European Union, United Kingdom and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy.2,3